These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 7993116)

  • 1. [Late phase II study with 21-consecutive-day oral administration of etoposide for malignant lymphoma].
    Yoshida T; Takagi T; Shimoyama M; Mikuni C; Suzuki K; Egami K; Furusawa S; Nomura T; Mori M; Sugimoto T
    Gan To Kagaku Ryoho; 1994 Dec; 21(16):2793-801. PubMed ID: 7993116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Late phase II clinical study of amrubicin hydrochloride, a novel synthetic anthracycline derivative anticancer agent, for malignant lymphoma].
    Akutsu M; Kano Y; Ogawa M; Miura A; Hirano M; Masaoka T; Tatsumi N
    Gan To Kagaku Ryoho; 2001 Nov; 28(12):1867-76. PubMed ID: 11729479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Early phase II trial of oral etoposide administered for 21 consecutive days in patients with cervical or ovarian cancer. ETP 21 Study Group--Cervical-Ovarian Cancer Group].
    Noda K; Tanaka K; Ozaki M; Hirabayasi K; Hasegawa K; Nishiya I; Yakushiji M; Izumi R; Tomoda Y; Ogita Y; Sugimori H; Yamabe T; Kudo R; Yajima A; Terashima Y; Fujii S; Suzuoki Y; Okada H; Kono I; Ochiai K; Yamamoto T; Ikeda M; Umesaki N; Saito T; Niitani H
    Gan To Kagaku Ryoho; 1998 Nov; 25(13):2061-8. PubMed ID: 9838908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Phase I clinical study of 21-consecutive-day oral administration of etoposide].
    Noda K; Fukuoka M; Komatsu H; Hayashihara K; Ariyoshi Y; Tanaka K; Nakajima H; Terashima Y; Nagao K; Furuse K
    Gan To Kagaku Ryoho; 1994 Aug; 21(10):1633-9. PubMed ID: 8060139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Late phase II trial of oral etoposide administered for 21 consecutive days in patients with cervical cancer. ETP 21 Study Group--Cervical Cancer Group].
    Ikeda M; Noda K; Hiura M; Tamaya T; Ozaki M; Hatae M; Ozawa M; Yamabe T; Tanaka K; Izumi R; Okada H; Ogita Y; Hoshiai H
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2249-57. PubMed ID: 9881082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Early phase II clinical trial of amrubicin hydrochloride in patients with malignant lymphoma].
    Masaoka T; Ogawa M; Inoue K; Sanpi K; Kuraishi Y; Toki H; Tamura K; Takagi T; Shibata A; Hirano M; Ezaki K; Shirakawa S; Matsuda T; Kimura I
    Gan To Kagaku Ryoho; 2001 Nov; 28(12):1857-65. PubMed ID: 11729478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Phase II study of etoposide (VP-16) in the form of oral capsules for malignant lymphomas].
    Konishi I; Kitani T; Nagai K; Kanamaru A; Kohsaki M; Masaoka T; Shibata H; Horiuchi A; Tsubaki K; Kawagoe H
    Gan To Kagaku Ryoho; 1985 Jul; 12(7):1482-6. PubMed ID: 4015122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Utility of daily oral administration of etoposide in 25 cases of refractory hematological malignancies].
    Kuga T; Kohda K; Matsumoto S; Nakazawa O; Ezoe A; Nobuoka A; Mochizuki C; Niitsu Y; Watanabe N
    Gan To Kagaku Ryoho; 1997 Feb; 24(3):315-21. PubMed ID: 9051134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Early phase II study of MST-16 (sobuzoxane) on malignant lymphoma].
    Tominaga N; Teshima H; Hiraoka A; Masaoka T; Ariyoshi Y; Suzuki H; Kimura I; Ohnoshi T; Hayashi K; Arima T
    Gan To Kagaku Ryoho; 1991 Nov; 18(14):2441-6. PubMed ID: 1952963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [MINE regimen for patients with relapsed or chemo-resistant invasive non-Hodgkin's lymphoma].
    Fan Y; Huang ZY; Luo LH; Yu HF
    Ai Zheng; 2005 Dec; 24(12):1503-6. PubMed ID: 16351801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Menogaril (TUT-7) late phase II study for malignant lymphoma, adult T-cell leukemia and lymphoma (ATLL)].
    Taguchi T; Ohta K; Hotta T; Shirakawa S; Masaoka T; Kimura I
    Gan To Kagaku Ryoho; 1997 Aug; 24(10):1263-71. PubMed ID: 9279345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [MTX-HOPE (methotrexate, hydrocortisone, vincristine, sobuzoxane, and etoposide) as a low-dose salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma].
    Tsunoda S; Kobayashi H; Inoue K; Izumi T; Akutsu M; Katano S; Ueda T; Shirai T; Masuda Y; Ohmine K; Nagashima T; Ueda M; Takagi S; Muroi K; Ozawa K; Kano Y
    Gan To Kagaku Ryoho; 2007 Jun; 34(6):885-9. PubMed ID: 17565251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of DICE (dexamethasone, etoposide, ifosfamide, and cisplatin) regimen on recurrent and refractory non-Hodgkin's lymphoma].
    Bo LJ; Liang AB; Liu B; Chen YH; Wang F; Jin XP
    Ai Zheng; 2006 Dec; 25(12):1553-6. PubMed ID: 17166385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Phase II study of etoposide (VP-16) in the form of intravenous injection for malignant lymphomas and acute leukemias: Hanshin Cooperative Study Group for Hematological Disorders].
    Tagawa S; Kitani T; Nagai K; Kanamaru A; Kohsaki M; Masaoka T; Shibata H; Horiuchi A; Tsubaki K; Kawagoe H
    Gan No Rinsho; 1987 Jan; 33(1):1-7. PubMed ID: 3469424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Phase II study of KRN8602 (MX2) for malignant lymphoma].
    Okabe K; Sampi K; Kuraishi Y; Takemoto Y; Tamura K; Ogawa M
    Gan To Kagaku Ryoho; 1998 Jun; 25(7):1001-6. PubMed ID: 9644314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
    Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
    Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
    Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.
    Borghaei H; Millenson M; Schilder R; Alden M; Rogatko A; Wang H; Padavic-Shaller K; Smith MR
    Cancer; 2004 Nov; 101(9):2034-41. PubMed ID: 15455357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Phase I study of an oral administration of VP 16-213].
    Ogawa M; Ota K; Oyama A; Fukuoka M; Takada M; Yoshida S; Sanpi K; Kimura I; Ohnoshi T; Kuraishi Y
    Gan To Kagaku Ryoho; 1983 Nov; 10(11):2403-7. PubMed ID: 6639102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
    Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
    Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.